Publications by authors named "Jordan E Eichholz"
Article Synopsis
- The study looked at patients with brain tumors caused by colorectal cancer to see how to better treat and watch them.
- Researchers wanted to find out what factors could help predict how long patients might live and how their tumors might grow after treatment with a specific therapy called stereotactic radiosurgery (SRS).
- The results showed that many patients with these brain tumors also have other cancer spreading in their body, and certain genetic changes in their tumors can help understand how their health might change after treatment.
Article Synopsis
- Researchers studied the association of circulating tumor DNA (ctDNA) with recurrence in patients with unresectable non-small cell lung cancer (NSCLC) following definitive radiation therapy, aiming for better disease management.
- A cohort of 17 patients had 70 plasma samples analyzed, revealing an 82% detection rate for ctDNA before treatment; however, only 35% were ctDNA-positive shortly after treatment, all of whom showed clinical progression.
- The findings indicated that ctDNA positivity significantly correlated with worse progression-free survival, suggesting that monitoring ctDNA could facilitate early recurrence detection and help identify patients who may need more aggressive treatment.
Introduction: Highly effective brain-penetrant ALK-targeted tyrosine kinase inhibitors (TKIs) have been developed for the management of NSCLC patients with brain metastases (BM). Local therapy (LT) such as SRS or therapeutic craniotomy is increasingly being deferred for such patients. Herein we report detailed patient- and lesion-level intracranial outcomes and co-mutational genomic profiles from a cohort of NSCLC patients with BM treated with alectinib, with or without LT.
View Article and Find Full Text PDFImportance: The addition of consolidative durvalumab to chemoradiation has improved disease control and survival in locally advanced non-small cell lung cancer (NSCLC). However, there remains a need to identify biomarkers for response to this therapy to allow for risk adaptation and personalization.
Objectives: To evaluate whether TMB or other variants associated with radiation response are also associated with outcomes following definitive chemoradiation and adjuvant durvalumab among patients with locally advanced unresectable NSCLC.
Introduction: Single-agent monoclonal antibody therapy against programmed death-ligand 1 (PD-L1) has modest effects in malignant pleural mesothelioma. Radiation therapy can enhance the antitumor effects of immunotherapy. Nevertheless, the safety of combining anti-PD-L1 therapy with stereotactic body radiation therapy (SBRT) is unknown.
View Article and Find Full Text PDF